BridgeBio Pharma Total Liabilities and Share Holders Equity 2018-2024 | BBIO
BridgeBio Pharma total liabilities and share holders equity from 2018 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
BridgeBio Pharma Annual Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2023 |
$546 |
| 2022 |
$623 |
| 2021 |
$1,013 |
| 2020 |
$704 |
| 2019 |
$632 |
| 2018 |
$465 |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2024-09-30 |
$665 |
| 2024-06-30 |
$794 |
| 2024-03-31 |
$849 |
| 2023-12-31 |
$546 |
| 2023-09-30 |
$655 |
| 2023-06-30 |
$504 |
| 2023-03-31 |
$626 |
| 2022-12-31 |
$623 |
| 2022-09-30 |
$729 |
| 2022-06-30 |
$862 |
| 2022-03-31 |
$813 |
| 2021-12-31 |
$1,013 |
| 2021-09-30 |
$782 |
| 2021-06-30 |
$1,081 |
| 2021-03-31 |
$1,093 |
| 2020-12-31 |
$704 |
| 2020-09-30 |
$788 |
| 2020-06-30 |
$905 |
| 2020-03-31 |
$990 |
| 2019-12-31 |
$632 |
| 2019-09-30 |
$641 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
|
| 2018-09-30 |
$0 |
| 2017-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
